|
|||||
|
|
| ERCC1和ERCC4基因多态性对NSCLC患者顺铂疗效的影响 | |
| 引用本文： | 华之卉,房文铮,赵忠全,解方为,欧阳学农,宋洪涛.ERCC1和ERCC4基因多态性对NSCLC患者顺铂疗效的影响[J].中国临床药理学与治疗学,2011,27(7):772-778. |
| 作者姓名： | 华之卉 房文铮 赵忠全 解方为 欧阳学农 宋洪涛 |
| 作者单位： | 1. 南京军区福州总医院药学科,福州,350025,福建;南京军区福州总医院肿瘤科,福州,350025,福建 2. 南京军区福州总医院肿瘤科,福州,350025,福建 3. 南京军区福州总医院药学科,福州,350025,福建 |
| 摘 要： | 目的:探讨ERCC1 C118T、ERCC4-673C>T基因多态性对以顺铂为基础化疗的非小细胞肺癌(NSCLC)患者疗效的影响。方法:采用多聚酶链反应-限制片断长度多态性(PCR-RFLP)法对接受以顺铂为基础化疗的NSCLC患者进行基因分型,并评价其化疗疗效及疾病进展情况,然后分析基因多态性与化疗疗效的相关性。结果:虽然未发现NSCLC患者ERCC1 C118T基因型间客观有效率及疾病控制率的差异,仍然可以看到携带C/C基因患者的客观有效率及疾病控制率均高于携带T突变等位基因患者(T/T+C/T)(29.6%vs20.6%,77.8%vs73.5%),而NSCLC患者无进展生存期(PFS)与ERCC1C118T基因多态性无关联性。携带ERCC4-673C>T野生型(C/C)患者疾病控制率略低于携带T等位基因型(C/T+T/T)患者(72.5%vs81.0%),但无统计学差异。未发现以顺铂为基础化疗的NSCLC患者客观有效率、PFS与ERCC4-673C>T基因多态性有关。结论:以顺铂为基础化疗的NSCLC患者疗效与ERCC1 C118T、ER-CC4-673C>T基因多态性可能无关。 |
| 关 键 词： | 非小细胞肺癌 顺铂 基因多态性 ER-CC1 ERCC4 |
Association study of ERCC1 and ERCC4 genetic polymorphism with response and survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy |
|
| HUA Zhi-hui,FANG Wen-zheng,ZHAO Zhong-quan,XIE Fang-wei,OU YANG Xue-nong,SONG Hong-tao.Association study of ERCC1 and ERCC4 genetic polymorphism with response and survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy[J].Chinese Journal of Clinical Pharmacology and Therapeutics,2011,27(7):772-778. | |
| Authors: | HUA Zhi-hui FANG Wen-zheng ZHAO Zhong-quan XIE Fang-wei OU YANG Xue-nong SONG Hong-tao |
| Institution: | HUA Zhi-hui1,2,FANG Wen-zheng3,ZHAO Zhong-quan3,XIE Fang-wei3,OU YANG Xue-nong3,SONG Hong-tao1 1Department of Pharmacy,Fuzhou General Hospital of Nanjing Command,Fuzhou 350025,Fujian,China,2School of Pharmacy,Shenyang Pharmaceutical University,Shenyang 110016,Liaoning,3Department of Oncology |
| Abstract: | AIM: To evaluate the effect of the polymorphisms of excision repair cross-complementation group 1(ERCC1) and excision repair cross-complementation group 4(ERCC4) on response and progress free survival in non-small cell lung cancer patients treated with cisplatin-based chemotherapy.METHODS: ERCC1 and ERCC4 were genetyped by polymerase chain reaction restriction fragment length polymorphism.The relationship between response,progress free survival and genetype was analyzed.RESULTS:Compared with patients carryi... |
| Keywords: | Non-small cell lung cancer Cisplatin Genetic polymorphism ERCC1 ERCC4 |
| 本文献已被 CNKI 万方数据 等数据库收录！ | |